Mouse Model Research Applications
Since 1998, ingenious targeting laboratory has mouse model generation supporting research across every major therapeutic area. Our models have contributed to more than 800 peer reviewed publications and advanced drug discovery programs from target validation through preclinical efficacy testing.
Mouse models remain essential tools for understanding disease mechanisms, validating therapeutic targets, and testing novel interventions before clinical trials. Ingenious targeting laboratory's expertise spans oncology, neuroscience, metabolic disease, immunology, cardiovascular research, rare diseases, and ophthalmology.
Start your project today
Our scientific consultants are ready to discuss your research requirements and recommend the optimal approach for your program. Initial consultation is provided at no charge.
Frequently asked questions
Mouse model generation are used for basic research (gene function studies, developmental biology, disease mechanisms), target validation (confirming therapeutic target relevance), drug discovery (preclinical testing, biomarker development), gene therapy development (AAV testing, therapeutic evaluation), and rare disease research (patient mutation modeling, therapeutic testing).
Target validation models demonstrate phenotypic consequences of target inhibition, disease pathway involvement, potential for therapeutic intervention, and safety signals from complete target elimination. Knockout or conditional knockout models provide definitive evidence for therapeutic target relevance before committing to drug discovery programs.
Yes. Reporter knockin models enable in vivo biomarker discovery and validation by visualizing gene expression patterns, cell populations, and pathway activation in living animals. Models enable tracking of biomarker expression during disease progression or treatment response, supporting translation to clinical assays.
Humanized models express human target genes, enabling preclinical testing of therapeutics that target human-specific proteins. This is particularly important for monoclonal antibodies with species-specific epitopes, checkpoint inhibitors requiring human immune molecules, and gene therapy approaches targeting human sequences.